Literature DB >> 15540956

Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events.

Paul E Langton, Graeme J Hankey, John W Eikelboom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15540956     DOI： 10.5694/j.1326-5377.2004.tb06433.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


× No keyword cloud information.
  3 in total

1.  Banning all drug promotion is the best option pending major reforms.

Authors:  Peter R Mansfield
Journal:  J Bioeth Inq       Date:  2005       Impact factor: 1.352

2.  Do selective cyclo-oxygenase-2 inhibitors have a future?

Authors:  Bernard Bannwarth
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market.

Authors:  Nadia Barozzi; Susan E Tett
Journal:  Clin Rheumatol       Date:  2009-01-09       Impact factor: 2.980
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.